ArticleInvestigative ophthalmology & visual science2026
GSH-Responsive PBAE Polymers for IL-12 mRNA Delivery in Melanoma Immunotherapy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Melanoma is a highly aggressive cancer with significant treatment challenges due to its immunosuppressive tumor microenvironment. Among its subtypes, uveal melanoma (UM), as a distinct subtype arising in the immune-privileged ocular site, currently lacks effective therapies to improve overall survival. Methods: We developed a glutathione (GSH)-responsive poly(β-amino ester) (PBAE) platform for intracellular IL-12 mRNA delivery. By optimizing the ratio of GSH-responsive diacrylate monomers and amine structures, we synthesized and screened a library of candidate polymers for transfection efficiency. Nanoparticle size, stability, GSH-triggered disassembly, and mRNA release were characterized. Cellular uptake, protein expression, endo/lysosomal escape, cytotoxicity, and systemic safety were assessed in vitro and in vivo. Efficacy was evaluated in subcutaneous, intraocular, and lung metastasis mouse models using the B16F10 melanoma cell line. Results: The optimized polymer PSS0.5-A2B2 formed stable mRNA-loaded nanoparticles (approximately 100 nm) and exhibited time-dependent disassembly under GSH-rich conditions, enabling efficient mRNA release and enhanced IL-12 expression. In vitro, it enhanced cellular uptake, IL-12 expression, and endo/lysosomal escape. In vivo, no significant systemic toxicity was observed. IL-12 mRNA delivery significantly suppressed tumor growth, promoted apoptosis, and reduced metastasis. Combined intravitreal and intravenous administration showed superior antitumor efficacy. Conclusions: This GSH-responsive PBAE platform enables biocompatible intracellular IL-12 mRNA delivery, offering a promising local-systemic combinatorial immunotherapy strategy for melanoma, holding potential promise for UM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.